Avalon Globocare (ALBT)

$3.66 +0.19 (5.58%)
Market Cap 3.79M
Revenue (ttm) 1.26M
Net Income (ttm) -16.71M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,326.19%
Debt to Equity Ratio 1.20
Volume 54,900
Avg Vol 1,763,414
Day's Range N/A - N/A
Shares Out 1.09M
Stochastic %K 60%
Beta 0.19
Analysts Strong Buy
Price Target N/A

Latest News on ALBT

Avalon GloboCare Launches “BrAce for Impact" Affiliate Marketing Program for the KetoAir Breathalyzer Device

Nov 18, 2024, 9:00 AM EST - 2 months ago

Avalon GloboCare Launches “BrAce for Impact" Affiliate Marketing Program for the KetoAir Breathalyzer Device

Avalon GloboCare and Qi Diagnostics Enter into Memorandum of Understanding for Proposed Co-Development of Real-Time Cannabis Breathalyzer for Detecting Potential Impaired Driving

Oct 25, 2024, 9:00 AM EDT - 3 months ago

Avalon GloboCare and Qi Diagnostics Enter into Memorandum of Understanding for Proposed Co-Development of Real-Time Cannabis Breathalyzer for Detecting Potential Impaired Driving

Avalon's Laboratory Services MSO Launches DNA Testing Kit for Predisposition to Opioid Addiction

Jul 31, 2024, 8:00 AM EDT - 6 months ago

Avalon's Laboratory Services MSO Launches DNA Testing Kit for Predisposition to Opioid Addiction

Avalon GloboCare Receives Notice from Nasdaq Regarding Delayed Quarterly Report

May 24, 2024, 5:00 PM EDT - 8 months ago

Avalon GloboCare Receives Notice from Nasdaq Regarding Delayed Quarterly Report

Avalon GloboCare Announces Launch of U.S. Sales of KetoAir Breathalyzer at the Hack Your Health by KetoCon 2024 Conference

Apr 22, 2024, 9:00 AM EDT - 9 months ago

Avalon GloboCare Announces Launch of U.S. Sales of KetoAir Breathalyzer at the Hack Your Health by KetoCon 2024 Conference

Avalon GloboCare Extends Exclusivity Agreement to Distribute KetoAir Breathalyzer Device and AI-Enabled Software in North America, South America, United Kingdom and European Union

Mar 28, 2024, 9:00 AM EDT - 10 months ago

Avalon GloboCare Extends Exclusivity Agreement to Distribute KetoAir Breathalyzer Device and AI-Enabled Software in North America, South America, United Kingdom and European Union

Avalon GloboCare Engages ChtrBx, a Marketing and Branding Company, to Launch KetoAir in the US

Dec 18, 2023, 9:00 AM EST - 1 year ago

Avalon GloboCare Engages ChtrBx, a Marketing and Branding Company, to Launch KetoAir in the US

Apple Approves Use of Avalon GloboCare's KetoAir Mobile Application

Oct 4, 2023, 9:00 AM EDT - 1 year ago

Apple Approves Use of Avalon GloboCare's KetoAir Mobile Application

Avalon's Laboratory Services MSO Acquires California-Based Medical Supply Company and Proprietary FDA-Registered External Male Catheter Device

Sep 13, 2023, 9:15 AM EDT - 1 year ago

Avalon's Laboratory Services MSO Acquires California-Based Medical Supply Company and Proprietary FDA-Registered External Male Catheter Device

Avalon's Laboratory Services MSO Launches Innovative Laboratory Test for Tuberculosis

Aug 30, 2023, 9:00 AM EDT - 1 year ago

Avalon's Laboratory Services MSO Launches Innovative Laboratory Test for Tuberculosis

Avalon's Laboratory Services MSO Announces Expansion into Arizona

Aug 21, 2023, 9:00 AM EDT - 1 year ago

Avalon's Laboratory Services MSO Announces Expansion into Arizona

Avalon's Laboratory Services MSO Acquires Texas Lab with Significant Potential Growth

Jul 24, 2023, 9:00 AM EDT - 1 year ago

Avalon's Laboratory Services MSO Acquires Texas Lab with Significant Potential Growth

Avalon GloboCare's Laboratory Services MSO Signs Exclusive In-Network Lab Services Agreement Providing Significant Expansion Opportunity into 21 States

Jul 19, 2023, 9:00 AM EDT - 1 year ago

Avalon GloboCare's Laboratory Services MSO Signs Exclusive In-Network Lab Services Agreement Providing Significant Expansion Opportunity into 21 States

Avalon GloboCare Provides Update on New Commercial Strategy

Jul 10, 2023, 9:00 AM EDT - 1 year ago

Avalon GloboCare Provides Update on New Commercial Strategy

Avalon GloboCare Reports Laboratory Services MSO Revenue of $14.7 Million and Net Income of $6.3 Million in 2022

Apr 27, 2023, 9:00 AM EDT - 1 year ago

Avalon GloboCare Reports Laboratory Services MSO Revenue of $14.7 Million and Net Income of $6.3 Million in 2022

Avalon GloboCare to Participate in the 35th Annual Roth Conference

Mar 3, 2023, 9:00 AM EST - 2 years ago

Avalon GloboCare to Participate in the 35th Annual Roth Conference

Avalon GloboCare Announces Closing of Strategic Investment in Laboratory Services MSO, a Leading Clinical Diagnostics and Reference Laboratory Company

Feb 13, 2023, 9:00 AM EST - 2 years ago

Avalon GloboCare Announces Closing of Strategic Investment in Laboratory Services MSO, a Leading Clinical Diagnostics and Reference Laboratory Company

Avalon GloboCare Announces Issuance of Key U.S. Patent for Multiple Novel QTY-Code Modified Cytokine and Chemokine Protein Receptor Molecules

Jan 17, 2023, 9:00 AM EST - 2 years ago

Avalon GloboCare Announces Issuance of Key U.S. Patent for Multiple Novel QTY-Code Modified Cytokine and Chemokine Protein Receptor Molecules

Avalon GloboCare Appoints Lourdes Felix, CEO of a Premier Addiction Treatment Company, to its Board of Directors

Jan 11, 2023, 9:00 AM EST - 2 years ago

Avalon GloboCare Appoints Lourdes Felix, CEO of a Premier Addiction Treatment Company, to its Board of Directors

Avalon GloboCare Announces the Deployment of Breakthrough Fusion Gene Map Technology

Jan 3, 2023, 9:00 AM EST - 2 years ago

Avalon GloboCare Announces the Deployment of Breakthrough Fusion Gene Map Technology

Avalon GloboCare Announces $4 Million Private Placement of Preferred Stock with the Company's Chairman which Converts at a Significant Premium to Market; Proceeds to Support Acquisition of Laboratory Services

Dec 14, 2022, 9:00 AM EST - 2 years ago

Avalon GloboCare Announces $4 Million Private Placement of Preferred Stock with the Company's Chairman which Converts at a Significant Premium to Market; Proceeds to Support Acquisition of Laboratory Services

Avalon GloboCare Continues its U.S. Centric Strategy with a New Proposed Board Composition in Preparation for Acquisition of Laboratory Services MSO, LLC

Dec 12, 2022, 9:00 AM EST - 2 years ago

Avalon GloboCare Continues its U.S. Centric Strategy with a New Proposed Board Composition in Preparation for Acquisition of Laboratory Services MSO, LLC

Avalon GloboCare Announces NASDAQ Ticker Symbol Change from “AVCO” to “ALBT”

Nov 9, 2022, 4:00 PM EST - 2 years ago

Avalon GloboCare Announces NASDAQ Ticker Symbol Change from “AVCO” to “ALBT”